BioNTech (BNTX) Competitors $110.02 -1.02 (-0.92%) Closing price 04:00 PM EasternExtended Trading$110.45 +0.43 (+0.39%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTX vs. GSK, TAK, ARGX, ONC, INSM, SMMT, TEVA, ITCI, GMAB, and MRNAShould you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. BioNTech vs. Its Competitors GSK Takeda Pharmaceutical argenex BeOne Medicines Insmed Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Moderna GSK (NYSE:GSK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Do analysts prefer GSK or BNTX? GSK presently has a consensus target price of $37.38, indicating a potential upside of 3.02%. BioNTech has a consensus target price of $136.58, indicating a potential upside of 24.14%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 1 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.11BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.83 Is GSK or BNTX more profitable? GSK has a net margin of 9.89% compared to BioNTech's net margin of -27.37%. GSK's return on equity of 48.82% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets GSK9.89% 48.82% 11.15% BioNTech -27.37%-3.94%-3.41% Do insiders and institutionals hold more shares of GSK or BNTX? 15.7% of GSK shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, GSK or BNTX? GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGSK$40.10B1.85$3.29B$1.9418.70BioNTech$2.98B8.88-$719.92M-$3.40-32.36 Does the media refer more to GSK or BNTX? In the previous week, GSK had 23 more articles in the media than BioNTech. MarketBeat recorded 32 mentions for GSK and 9 mentions for BioNTech. BioNTech's average media sentiment score of 0.56 beat GSK's score of 0.45 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 10 Very Positive mention(s) 8 Positive mention(s) 4 Neutral mention(s) 5 Negative mention(s) 5 Very Negative mention(s) Neutral BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, GSK or BNTX? GSK has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. SummaryGSK beats BioNTech on 9 of the 16 factors compared between the two stocks. Get BioNTech News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTX vs. The Competition Export to ExcelMetricBioNTechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.69B$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-32.368.2821.0120.09Price / Sales8.88303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book1.267.678.125.65Net Income-$719.92M-$55.28M$3.25B$257.91M7 Day Performance-2.54%2.50%0.97%2.09%1 Month Performance5.38%11.70%7.36%11.13%1 Year Performance27.38%4.89%31.31%18.40% BioNTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTXBioNTech1.4591 of 5 stars$110.02-0.9%$136.58+24.1%+28.4%$26.69B$2.98B-32.366,772Analyst ForecastGSKGSK1.9089 of 5 stars$38.34+0.1%$37.38-2.5%-8.4%$78.49B$40.10B19.7668,629Trending NewsTAKTakeda Pharmaceutical2.0054 of 5 stars$15.04+2.4%N/A+7.6%$47.84B$30.09B68.3447,455Positive NewsHigh Trading VolumeARGXargenex4.4966 of 5 stars$561.28+0.2%$728.06+29.7%+23.6%$34.35B$2.25B34.631,599Positive NewsAnalyst RevisionONCBeOne Medicines2.5583 of 5 stars$252.14+0.7%$320.67+27.2%N/A$27.63B$3.81B-67.7811,000Analyst ForecastGap UpINSMInsmed3.8659 of 5 stars$101.89+3.8%$108.07+6.1%+37.9%$19.33B$381.03M-17.121,271Positive NewsAnalyst ForecastInsider TradeSMMTSummit Therapeutics2.886 of 5 stars$25.40+1.6%$34.67+36.5%+196.8%$18.86BN/A-74.70110TEVATeva Pharmaceutical Industries4.1195 of 5 stars$16.43+0.2%$24.71+50.5%-0.4%$18.84B$16.54B-14.2836,830ITCIIntra-Cellular Therapies0.9187 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9168 of 5 stars$21.46+0.3%$37.80+76.1%-18.0%$13.77B$3.12B12.192,682Analyst RevisionMRNAModerna4.2835 of 5 stars$32.87-2.3%$46.61+41.8%-74.0%$12.71B$3.24B-3.775,800Trending NewsOptions VolumeAnalyst Revision Related Companies and Tools Related Companies GSK Competitors Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors Insmed Competitors Summit Therapeutics Competitors Teva Pharmaceutical Industries Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Moderna Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNTX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.